A screening from the cancer therapeutics response portal (https://portals.broadinstitute.org/ctrp/) to find molecule drugs that target the JAK/STAT cascade more selectively, confirmed that momemolitib was one of the most effective molecules to inhibit STAT5 signaling (Additional file 3: Figure S5b). The gene discussed is SOAT1; the disease is cancer.